[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100270750":3},{"organization":4,"outcomesModule":7,"designInfo":15,"detailedDescription":11,"studyPopulation":11,"armGroups":23,"interventions":36,"overallOfficials":43,"centralContacts":47,"locations":57,"responsibleParty":85,"collaborators":87,"id":90,"slug":11,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":91,"sex":97,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":11,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":11,"overallStatus":74,"whyStopped":11,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":118},{"fullName":5,"class":6},"Istituto Auxologico Italiano","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9,13],{"measure":10,"description":11,"timeFrame":12},"changes in LVMI (co-primary endpoint)",null,"12 months",{"measure":14,"description":11,"timeFrame":12},"UAE (albumin\u002Fcreatinine ratio, co-primary end-point)",{"allocation":16,"interventionModel":17,"interventionModelDescription":11,"primaryPurpose":18,"observationalModel":11,"timePerspective":11,"maskingInfo":19},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":20,"maskingDescription":11,"whoMasked":21},"SINGLE",[22],"OUTCOMES_ASSESSOR",[24,30],{"label":25,"type":26,"description":27,"interventionNames":28},"Group 1","ACTIVE_COMPARATOR","Management strategy of blood pressure based on office BP as a guide to treatment",[29],"Other: Optimization of antihypertensive treatment based on office BP",{"label":31,"type":32,"description":33,"interventionNames":34},"Group 2","EXPERIMENTAL","Management strategy of blood pressure based on 24-hour ABPM as a guide to treatment",[35],"Other: Optimization of antihypertensive treatment based on 24-hour ABPM",[37,40],{"type":6,"name":38,"description":38,"armGroupLabels":39,"otherNames":11},"Optimization of antihypertensive treatment based on office BP",[25],{"type":6,"name":41,"description":41,"armGroupLabels":42,"otherNames":11},"Optimization of antihypertensive treatment based on 24-hour ABPM",[31],[44],{"name":45,"affiliation":5,"role":46},"Gianfranco Parati, MD","PRINCIPAL_INVESTIGATOR",[48,53],{"name":45,"role":49,"phone":50,"phoneExt":51,"email":52},"CONTACT","+390261911","2890","gianfranco.parati@unimib.it",{"name":54,"role":49,"phone":50,"phoneExt":55,"email":56},"Alberto Zanchetti, MD","2901","alberto.zanchetti@auxologico.it",[58,72],{"facility":5,"status":59,"city":60,"state":11,"zip":11,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"NOT_YET_RECRUITING","Milan","Italy","IT",{"type":64,"coordinates":65},"Point",[66,67],9.18951,45.46427,{"lat":67,"lon":66},[70],{"name":45,"role":49,"phone":71,"phoneExt":51,"email":52},"390261911",{"facility":73,"status":74,"city":75,"state":11,"zip":11,"country":76,"countryCode":11,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Fundacion Venezolana de Hipertension Arterial\u002FInstituto de Enfermedades Cardiovasculares de LUZ","RECRUITING","Maracaibo","Venezuela",{"type":64,"coordinates":78},[79,80],-71.61089,10.64232,{"lat":80,"lon":79},[83],{"name":84,"role":49,"phone":11,"phoneExt":11,"email":11},"Egle Silva, MD",{"type":86,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[88],{"name":89,"class":6},"European Society of Hypertension","100270750",false,"NCT02804074","MASked-unconTrolled hypERtension Management Based on Office BP or on Out-of-office (Ambulatory) BP Measurement","MASked-unconTrolled hypERtension Management Based on Office BP or on Out-of-office (Ambulatory) BP Measurement (MASTER Study)","MASTER","Inclusion Criteria:\n\n* Male and female subjects\n* Age 35-80 years\n* Masked uncontrolled (in treatment) hypertension: office BP \\\u003C140\u002F90 mmHg, and one or more of the following situations:\n\n  * Ambulatory daytime BP \\>135\u002F85 mmHg\n  * Ambulatory night-time ABP \\> 120\u002F70 mmHg\n  * Ambulatory 24h ABP \\>130\u002F80 mmHg\n* eGFR ≥45 mL\u002Fmin\u002F1.73 m2 (CKD-EPI creatinine equation 2009)\n\nExclusion Criteria:\n\n* eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m2 (CKD-EPI creatinine equation 2009), and in particular severe chronic renal failure defined as serum creatinine \\> 250 umol\u002Fl;\n* Patients in unstable clinical conditions;\n* Known secondary hypertension;\n* Orthostatic hypotension (SBP fall \\> 20 mmHg on standing);\n* Dementia (clinical diagnosis);\n* Hepatic disease as determined by either AST or ALT values \\> 2 times the upper limit of normal\n* History of gastrointestinal surgery or disorders which could interfere with drug absorption\n* Known allergy or contraindications to one of the drugs to be administered in the study\n* History of malignancy including leukaemia and lymphoma (but not basal cell skin cancer) within the last 5 years\n* History of clinically significant autoimmune disorders such as systemic lupus erythematosus.\n* History of drug or alcohol abuse within the last 5 years\n* History of non-compliance to medical regimens and\u002For patients who are considered potentially unreliable\n* Inability or unwillingness to give free informed consent\n* Pregnancy or planned pregnancy during study period.","ALL","35 Years","80 Years",{"count":101,"type":102},1240,"ESTIMATED","INTERVENTIONAL",[105],"NA","MASTER study is a 4-year prospective, randomized, open-label, blinded-endpoint study (PROBE) comparing 2 management strategies 1) office BP as a guide to treatment, or 2) 24-hour ABP as a guide to treatment. Study objectives are to investigate whether a management strategy based on out-of-office BP (Ambulatory BP monitoring) versus a management strategy based on office BP measurements is associated with differences in outcome, including cardiovascular and renal intermediate end points at one year; cardiovascular events at 4 years and changes in a number of blood pressure-related variables throughout the study. Patients will be followed-up during the first year focusing on changes in left ventricular mass index (LVMI, co-primary endpoint) and Urinary albumin excretion (UAE, albumin\u002Fcreatinine ratio, co-primary end-point), and during the whole 48 month period for both changes in LVMI and UAE and events including all-cause mortality, CV morbidity and mortality, cerebral morbidity and mortality.A total of 1240 subjects will be recruited by 30 centers, taking into account a dropout rate of 15% (620 subjects per randomization arm).",[108],"Masked Hypertension","2026-03-25",{"date":111,"type":112},"2026-03-30","ACTUAL",{"date":114,"type":112},"2018-10-01",{"date":116,"type":102},"2026-12",{"name":5,"class":6},2]